Handelsbanken Fonder AB Raises Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Handelsbanken Fonder AB grew its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 13.0% in the 4th quarter, HoldingsChannel reports. The firm owned 54,041 shares of the biopharmaceutical company’s stock after purchasing an additional 6,200 shares during the quarter. Handelsbanken Fonder AB’s holdings in Amicus Therapeutics were worth $767,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its holdings in Amicus Therapeutics by 97.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,368 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 3,638 shares in the last quarter. Park Avenue Securities LLC acquired a new position in shares of Amicus Therapeutics in the third quarter worth $128,000. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Amicus Therapeutics during the third quarter worth $134,000. Los Angeles Capital Management LLC acquired a new stake in shares of Amicus Therapeutics in the third quarter valued at $158,000. Finally, O Shaughnessy Asset Management LLC boosted its holdings in Amicus Therapeutics by 25.3% in the third quarter. O Shaughnessy Asset Management LLC now owns 15,243 shares of the biopharmaceutical company’s stock valued at $185,000 after purchasing an additional 3,082 shares during the period.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on FOLD shares. JPMorgan Chase & Co. cut their price target on Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Monday, March 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $22.00 target price on shares of Amicus Therapeutics in a report on Thursday, February 29th.

Insider Activity at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 4,167 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $14.00, for a total transaction of $58,338.00. Following the sale, the chief executive officer now owns 871,219 shares of the company’s stock, valued at $12,197,066. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Director Margaret G. Mcglynn sold 7,500 shares of the business’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $13.40, for a total value of $100,500.00. Following the completion of the sale, the director now directly owns 59,289 shares of the company’s stock, valued at approximately $794,472.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bradley L. Campbell sold 4,167 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $14.00, for a total value of $58,338.00. Following the completion of the sale, the chief executive officer now directly owns 871,219 shares of the company’s stock, valued at $12,197,066. The disclosure for this sale can be found here. Insiders sold 48,108 shares of company stock valued at $662,605 over the last three months. 2.10% of the stock is owned by corporate insiders.

Amicus Therapeutics Stock Performance

Shares of FOLD stock opened at $10.25 on Tuesday. Amicus Therapeutics, Inc. has a 12 month low of $9.70 and a 12 month high of $14.57. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 2.42. The company has a market cap of $3.04 billion, a P/E ratio of -20.10 and a beta of 0.75. The firm has a fifty day moving average price of $11.81 and a 200 day moving average price of $12.00.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.05). Amicus Therapeutics had a negative return on equity of 119.46% and a negative net margin of 37.96%. The business had revenue of $115.08 million for the quarter, compared to analyst estimates of $115.11 million. Sell-side analysts predict that Amicus Therapeutics, Inc. will post 0.01 earnings per share for the current fiscal year.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.